Sep 07, 2023 / 12:00PM GMT
Operator
Good day, ladies and gentlemen, and thank you for joining CymaBay's Phase III RESPONSE trial top line results conference call. (Operator Instructions) Please be advised that the call will be recorded at the company's request. It is also being webcast live on the Investors section at the CymaBay website at www.cymabay.com.
Now I'd like to turn the call over to Mr. Paul Quinlan, General Counsel at CymaBay. Thank you, sir. Please go ahead.
Paul T. Quinlan - CymaBay Therapeutics, Inc. - General Counsel, Chief Compliance Officer & Corporate Secretary
Thank you, operator. This morning, we issued a press release announcing top line results from the Phase III pivotal RESPONSE trial evaluating seladelpar in patients with primary biliary cholangitis, or PBC. You can access that release along with slides that support our discussion today on our website under the Investors tab.
Joining me on the call today are Sujal Shah, Chief Executive Officer; Chuck McWherter, Chief Scientific Officer
CymaBay Therapeutics Inc To Discuss Topline Results From The Phase 3 Pivotal Response Study Call Transcript
Sep 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers